Search

Your search keyword '"De Munck, Floris"' showing total 4 results
Start Over Author "De Munck, Floris"
4 results on '"De Munck, Floris"'

2. Clumping arachnoiditis in an unsuspected population: MRI appearance and etiology

Author

De Munck, Floris

Subjects
Inflammation, Complications, MR, Treatment effects, Neuroradiology spine
Abstract

Learning objectives Background Imaging findings OR Procedure details Conclusion Personal Information References, Learning objectives: To illustrate the use of axial T2-weighted images as an importanttool to diagnose clumping arachnoiditis. In this poster we show the normal axial appearance of the lumbar nerve roots compared to the imaging of clumped lumbar nerve roots. The aim is...

Published
2012
Full Text
View/download PDF

3. Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases

Author

Neyns, Bart, Aerts, Maridi, Van Nieuwenhove, Yves, Fontaine, Christel, De Coster, Lore, Schallier, Denis, Vanderauwera, Jacques, De Munck, Floris, Vandenbroucke, Frederik, Everaert, Hendrik, Meert, Vanessa, De Mey, Johan, De Ridder, Mark, Delvaux, Georges, De Greve, Jacques, Neyns, Bart, Aerts, Maridi, Van Nieuwenhove, Yves, Fontaine, Christel, De Coster, Lore, Schallier, Denis, Vanderauwera, Jacques, De Munck, Floris, Vandenbroucke, Frederik, Everaert, Hendrik, Meert, Vanessa, De Mey, Johan, De Ridder, Mark, Delvaux, Georges, and De Greve, Jacques

Abstract

Background: Both hepatic arterial infusion (HAI) of chemotherapy and cetuximab (CET) have interesting activity for the treatment of colorectal cancer liver metastases (CRC-LM). Patients and Methods: Intravenous CET with HAI oxaliplatin (OXA) or i.v. Irinotecan (IRI) followed by HAI of infusion of folic acid modulated 5-fluorouracil 5-FU/l-FA was administered to patients (pts) with CRC-LM who had failed at least one line of prior chemotherapy. Results: Eight pts received i.v. CET with HAI-OXA (5 pts) and i.v.-IRI (3 pts) and HAI-S-FU/I-FA. Adverse events: repeated grade 3 skin toxicity (1 pt), abdominal pain with elevated liver enzymes and asthenia (2 pts), duodenal ulcer (2 pts) with catheter migration and intestinal bleeding (1 pt), reversible interstitial pneumonitis (1 pt), and cystic bile duct dilatation (2 pts) with arteriobiliary fistulisation (1 pt). A partial response was documented in 5 pts (62%). The median time to progression was 8.7 months (95% confidence interval 8-14 months). Conclusion: Intravenous administration of CET with HAI of chemotherapy is feasible and has promising activity but is associated with specific toxicity., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2008

4. Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases.

Author

Neyns B, Aerts M, Van Nieuwenhove Y, Fontaine C, De Coster L, Schallier D, Vanderauwera J, De Munck F, Vandenbroucke F, Everaert H, Meert V, De Mey J, De Ridder M, Delvaux G, and De Grève J

Subjects
Adenocarcinoma pathology, Adult, Aged, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cetuximab, Colorectal Neoplasms pathology, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Hepatic Artery, Humans, Infusions, Intra-Arterial, Male, Middle Aged, Organoplatinum Compounds administration & dosage, Organoplatinum Compounds adverse effects, Oxaliplatin, Adenocarcinoma drug therapy, Adenocarcinoma secondary, Antibodies, Monoclonal administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Colorectal Neoplasms drug therapy, Liver Neoplasms drug therapy, Liver Neoplasms secondary
Abstract

Background: Both hepatic arterial infusion (HAI) of chemotherapy and cetuximab (CET) have interesting activity for the treatment of colorectal cancer liver metastases (CRC-LM)., Patients and Methods: Intravenous CET with HAI oxaliplatin (OXA) or i.v. Irinotecan (IRI) followed by HAI of infusion of folic acid modulated 5-fluorouracil 5-FU/l-FA was administered to patients (pts) with CRC-LM who had failed at least one line of prior chemotherapy., Results: Eight pts received i.v. CET with HAI-OXA (5 pts) and i.v.-IRI (3 pts) and HAI-5-FU/l-FA. Adverse events: repeated grade 3 skin toxicity (1 pt), abdominal pain with elevated liver enzymes and asthenia (2 pts), duodenal ulcer (2 pts) with catheter migration and intestinal bleeding (1 pt), reversible interstitial pneumonitis (1 pt), and cystic bile duct dilatation (2 pts) with arteriobiliary fistulisation (1 pt). A partial response was documented in 5 pts (62%). The median time to progression was 8.7 months (95% confidence interval 8-14 months)., Conclusion: Intravenous administration of CET with HAI of chemotherapy is feasible and has promising activity but is associated with specific toxicity.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results